Mocravimod and S1P Receptor Modulators Publications
A selection of publications are listed here. For more information on other research fields, or for further materials, get in touch with our Research Team info@priothera.com
Exploring Mocravimod: Key Research Highlights
Mocravimod improves overall survival in AML patients undergoing allogeneic hematopoietic cell transplantation
Medinger et al.
Mocravimod, an S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation
Dertschnig et al.
Mocravimod ameliorates chronic graft-versus-host disease after mouse allogeneic HCT
Zhang et al.
Mocravimod, a selective sphingosine-1-phosphate receptor modulator, in allogeneic hematopoietic cell transplantation for malignancy
Dertschnig et al.
Mocravimod, an S1P receptor agonist, increases both T cell counts in bone marrow biopsies from patients undergoing allogeneic HCT and acute GvHD-freedom probability
Medinger et al
A two-part, single- and two-arm randomized, open-label study to evaluate the safety, tolerability and pharmacokinetics of KRP203 in subjects with hematological malignancies undergoing allogeneic hematopoietic cell transplantation
Dertschnig et al.
Publications about other S1P Receptor Modulators
Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1P receptor agonists
Perez-Jeldres et al.
S1P signaling: new therapies and opportunities
Gonzalez-Cabrera et al.
Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GvHD)
Taylor et al.